Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $48.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 71.43% from the company’s current price.

A number of other analysts have also weighed in on DNTH. Wedbush reduced their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average price target of $45.13.

Dianthus Therapeutics Price Performance

DNTH opened at $28.00 on Thursday. The stock’s 50 day moving average price is $27.89 and its 200 day moving average price is $26.22. The stock has a market cap of $821.77 million, a P/E ratio of -4.80 and a beta of 1.85. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities analysts anticipate that Dianthus Therapeutics will post -2.32 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics during the fourth quarter valued at about $1,404,000. Octagon Capital Advisors LP boosted its stake in Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in Dianthus Therapeutics in the 1st quarter worth approximately $630,000. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Finally, StemPoint Capital LP acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at $1,304,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.